CHAPTER ONE: EXECUTIVE SUMMARY

Save this PDF as:

Size: px
Start display at page:

Download "CHAPTER ONE: EXECUTIVE SUMMARY"

Transcription

1 CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS Overview Introduction to Pathogens Demographics of the World Life Expectancy Infections and Drug Resistance Causes of Drug Resistance Drug Resistance in Select Populations Measures for Reducing Resistance HIV Trends Manufacturer and Marketer Trends Trends in Partnerships and Alliances Developers Trends Aradigm ARD-3100 Phase II Cystic fibrosis ARD-3150 Phase II Bronchiectasis ARD-1100 Preclinical Inhalation anthrax Trends in Rx-to-OTC Switches CHAPTER THREE: ANTIFUNGAL DRUGS Overview Types of Fungal Infections Superficial Systemic General Fungal Infection Statistics Fungal Infection Risk Description of Antifungal Products Systemic Antifungals Topical Antifungals

2 Market Overview Total Market Size and Forecast Antifungal Market by Product Type Antifungal Market by Geographical Region Market Analysis by Treated Condition Competitive Analysis Leading Products CHAPTER FOUR: ANTIBACTERIAL DRUGS Overview Classification of Antibacterial Organisms Antimicrobial Spectrum Bacterial Resistance Principles of Anti-bacterial Therapy Combination Therapy and Prophylactic Use Bacterial Infection Statistics Bacterial Infection Risk Classifications of Antibacterial Products Aminoglycosides Carbapenems Cephalosporins Macrolides Penicillins Quinolones Sulfonamides Tetracyclines Market Overview Total Market Size and Forecast Antibacterial Market by Product Type Antibacterial Market by Geographical Region Market Analysis by Treated Condition Competitive Analysis Leading Products CHAPTER FIVE: ANTIVIRAL DRUGS Overview: Introduction to Viruses Examples of Pathogenic Viruses Virus Function and Life History Replication in DNA Viruses Replication of RNA Viruses Replication in Retroviruses Host Defenses Against Viruses 8 Viral Ploys to Invade Host Cells and Circumvent Host Responses Invasion of Host Cells

3 Subversion of the Immune Response Avoidance of Immune Detection and Attack by Killer Cells HIV and AIDS Viral Infection Statistics Description of Antivirals Products Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors Protease Inhibitors Other Antivirals Market Overview Total Market Size and Forecast Antiviral Market by Product Type Antiviral Market by Geographical Region Market Analysis by Treated Condition Competitive Analysis Leading Products CHAPTER SIX: MARKET SUMMARY Market by Product Segment (Antifungals, Antibacterials, Antivirals) CHAPTER SEVEN: CORPORATE PROFILES Introduction Abbott Laboratories Astellas AstraZeneca Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma) Bristol-Myers Squibb Cubist Daiichi Sankyo Gilead Sciences GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Roche APPENDIX: COMPANY DIRECTORY TABLE OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: The Global Market for Anti-Infectives by Product Segment,

4 Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011 Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS Table 2-1: World Population by Selected Geographical Region, Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009 Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009 Table 2-3: Worldwide HIV/AIDS Infections Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle- Income Countries, 2009 based on 2010 WHO Guidelines Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle- Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines Table 2-7: Anti-Infective Drugs in Development by Developer Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year CHAPTER THREE: ANTIFUNGAL DRUGS Table 3-1: Incidence of Infections by Type, 2010 Figure 3-1: Incidence of Infections by Type, 2010 Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010 Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010 Table 3-3: Treatment Options for Fungal Infections, (Type, Brand, and Manufacturer) Table 3-4: The World Market for Antifungal Drugs Figure 3-3: The World Market for Antifungal Drugs Table 3-5: Antifungal Drug Market by Type , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Figure 3-4: The World Market for Antifungal Drugs Revenues by Type , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015, (Allylamines, Azoles, Polyene Macrolides, Other Antifungals) Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type, (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections) Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

5 Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products CHAPTER FOUR: ANTIBACTERIAL DRUGS Table 4-1: Antibiotics with Difficult Penetration Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010 Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010 Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010 Table 4-4: Treatment Options for Bacterial Infections, (Type, Brand, and Manufacturer) Table 4-5: The World Market for Antibacterial Drugs Figure 4-3: The World Market for Antibacterial Drugs Table 4-6: Antibacterial Drug Market by Type Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others) Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015, (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others) Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type, (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections) Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011, (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections) Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers

6 Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products CHAPTER FIVE: ANTIVIRAL DRUGS Table 5-1: Host Cell Receptors Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010 Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections Table 5-3: Treatment Options for Viral Infections, (Type, Brand, and Manufacturer) Table 5-4: The World Market for Antiviral Drugs Figure 5-2: The World Market for Antiviral Drugs Table 5-5: Antiviral Drug Market by Type Figure 5-3: The World Market for Antiviral Drugs Revenues by Type, (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) Figure 5-4: The World Market for Antiviral Drugs Revenues by Type, (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015 Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total) Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total) Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products CHAPTER SIX: MARKET SUMMARY Table 6-1: The Global Market for Anti-Infectives by Product Segment, Figure 6-1: The World Market for Anti-Infective Drugs Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011 Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION

More information

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α. Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01

More information

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST

More information

PHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS

PHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 INTENDED AUDIENCE 2 SCOPE OF REPORT 2 METHODOLOGY 2 INFORMATION SOURCES 2 ANALYST CREDENTIALS 3 RELATED

More information

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),

More information

BUGS and DRUGS Part 2 March 13, 2013 Marieke Kruidering- Hall

BUGS and DRUGS Part 2 March 13, 2013 Marieke Kruidering- Hall BUGS and DRUGS Part March, 0 Marieke Kruidering- Hall BIOGRAPHY: Marieke Kruidering- Hall is Associate Professor in the Department of Cellular & Molecular Pharmacology. She was born in the Netherlands.

More information

Influenza Vaccination Market Research Report Global Forecast till 2023

Influenza Vaccination Market Research Report Global Forecast till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR

More information

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude

More information

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

The US Onychomycosis Market (2017 Edition) July 2017

The US Onychomycosis Market (2017 Edition) July 2017 The US Onychomycosis Market (2017 Edition) July 2017 The US Onychomycosis Market Report Scope of the Report The report entitled The US Onychomycosis Market (2017 Edition), provides analysis of the US onychomycosis

More information

John Ansell President, John Ansell Consultancy Thame, UK

John Ansell President, John Ansell Consultancy Thame, UK Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1

More information

Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association

Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic

More information

BRIC DIABETES DRUGS MARKET

BRIC DIABETES DRUGS MARKET BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a

More information

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question Microbiology - Problem Drill 16: Antibiotics No. 1 of 10 1. An effective chemotherapeutic drug should have. (A) Low therapeutic index (B) More toxicity (C) Selective toxicity (D) Mutation inducing properties

More information

U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE

U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC

More information

The Data Collection on Adverse events of Anti-HIV Drugs

The Data Collection on Adverse events of Anti-HIV Drugs Dias 1 The Data Collection on Adverse events of Anti-HIV Drugs Ole Kirk, University of Copenhagen Denmark Dias 2 The Need for D:A:D February 1999, EMEA/Committee for Medicinal Products for Human Use (CHMP)

More information

ADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments

ADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS...

More information

Oncology Pipeline Analytics

Oncology Pipeline Analytics Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to

More information

(Incidence, Treatments, Key Companies, Pipeline and Trends)

(Incidence, Treatments, Key Companies, Pipeline and Trends) World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and

More information

Organ Transplantation Market Research Report- Global Forecast Till 2023

Organ Transplantation Market Research Report- Global Forecast Till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR

More information

Study Guide 23, 24 & 47

Study Guide 23, 24 & 47 Study Guide 23, 24 & 47 STUDY GUIDE SECTION 23-3 Bacteria and Humans Name Period Date 1. One bacterial disease that is transmitted by contaminated drinking water is a. Lyme disease b. gonorrhea c. tuberculosis

More information

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin

More information

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...

More information

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major

More information

Antiviral Drugs Lecture 5

Antiviral Drugs Lecture 5 Antiviral Drugs Lecture 5 Antimicrobial Chemotherapy (MLAB 366) 1 Dr. Mohamed A. El-Sakhawy 2 Introduction Viruses are microscopic organisms that can infect all living cells. They are parasitic and multiply

More information

Case No COMP/M BRISTOL MYERS SQUIBB / DU PONT. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 09/08/2001

Case No COMP/M BRISTOL MYERS SQUIBB / DU PONT. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 09/08/2001 EN Case No COMP/M.2517 - BRISTOL MYERS SQUIBB / DU PONT Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 09/08/2001 Also

More information

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market

More information

Immunity and Infection. Chapter 17

Immunity and Infection. Chapter 17 Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal

More information

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,

More information

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular

More information

CHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40

CHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 BCC

More information

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent

More information

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017: SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM

More information

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market

More information

Vaccine Technologies and Global Markets

Vaccine Technologies and Global Markets A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious

More information

Sickle-cell Anemia Therapeutics Market in the US

Sickle-cell Anemia Therapeutics Market in the US Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market

More information

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND

More information

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602

More information

Horizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007

Horizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007 Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research

More information

Europe Ginseng Market Report 2016

Europe Ginseng Market Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Ginseng Market Report 2016 Europe Ginseng Market Report 2016 Publication ID: QYR12167206 Publication December

More information

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and

More information

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast

More information

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013 PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012

More information

Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013

Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013 Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013 1 Summary: Community Antibiotic Use The rate for Quarter 1 of 2013 (1 st January to 31 st March) was 27.4 Defined Daily

More information

Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016

Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016 Global Magnetic Resonance Imaging (MRI)

More information

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38 CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

Custom Intelligence. Alzheimer s Disease Landscape Summary

Custom Intelligence. Alzheimer s Disease Landscape Summary Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic

More information

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general

More information

Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research

Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research The global visceral pain market size was estimated at USD 9.51 billion in 2016 and is expected to

More information

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and

More information

Dealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep

Dealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:

More information

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements

More information

Antimicrobial resistance Fact sheet N 194 Updated April 2014

Antimicrobial resistance Fact sheet N 194 Updated April 2014 Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by

More information

Antibacterials and Antivirals

Antibacterials and Antivirals Structure of a Bacterium: Antibacterials and Antivirals Capsule: protective layer made up of proteins, sugars and lipids Cell wall: provides the bacteria with its shape and structure Cell membrane: permeable

More information

JAK AND PI3K SIGNALING PATHWAY MARKETS

JAK AND PI3K SIGNALING PATHWAY MARKETS JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Operatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems

Operatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...

More information

Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016

Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Global Standard Radiography Film

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

1. Virus 2. Capsid 3. Envelope

1. Virus 2. Capsid 3. Envelope VIRUSES BIOLOGY II VOCABULARY- VIRUSES (22 Words) 1. Virus 2. Capsid 3. Envelope 4. Provirus 5. Retrovirus 6. Reverse transcriptase 7. Bacteriophage 8. Lytic Cycle 9. Virulent 10. Lysis 11. Lysogenic Cycle

More information

Global Oil Softgel Capsules Market Research Report 2016

Global Oil Softgel Capsules Market Research Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oil Softgel Capsules Market Research Report 2016 Global Oil Softgel Capsules Market Research Report 2016

More information

11/15/2011. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Viral Genomes. Structural Features and Characteristics

11/15/2011. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Viral Genomes. Structural Features and Characteristics Chapter 19 - Viruses Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV II. Prions The Good the Bad and the Ugly Viruses fit into the bad category

More information

Antiviral Chemotherapy

Antiviral Chemotherapy 12 Antiviral Chemotherapy Why antiviral drugs? Vaccines have provided considerable success in preventing viral diseases; However, they have modest or often no therapeutic effect for individuals who are

More information

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,

More information

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013 Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU

More information

CHAPTER THREE: INDUSTRY OVERVIEW... 6 STRUCTURE AND HISTORY OF THE DENTAL INDUSTRY... 6 STRUCTURE AND HISTORY (CONTINUED)... 8

CHAPTER THREE: INDUSTRY OVERVIEW... 6 STRUCTURE AND HISTORY OF THE DENTAL INDUSTRY... 6 STRUCTURE AND HISTORY (CONTINUED)... 8 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC RESEARCH ONLINE

More information

How HIV Works in Your Body

How HIV Works in Your Body How HIV Works in Your Body It helps to know what s going on with your virus What is HIV and how do people get it? The initials HIV stand for Human Immunodeficiency Virus meaning a virus that causes the

More information

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological

More information

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU

More information

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018 Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities

More information

Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis

Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis Introduction This report examines treatment protocols evolved over

More information

Contraceptives: Technologies and Global Markets

Contraceptives: Technologies and Global Markets A BCC Research Healthcare Report HLC085A Use this report to: Learn how shifting demographic and sociological factors such as population growth, proportion of young population, and perceptions about family

More information

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification

More information

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

Current and future market dynamics overview

Current and future market dynamics overview OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast

More information

The Global Health Impact Index

The Global Health Impact Index The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine

More information

Immune System. Name: Class: Date: Multiple Choice Identify the choice that best completes the statement or answers the question.

Immune System. Name: Class: Date: Multiple Choice Identify the choice that best completes the statement or answers the question. Class: Date: Immune System Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the bacteria is the cause of pneumonia? a. staphylococci c. Treponema

More information

Overview: Chapter 19 Viruses: A Borrowed Life

Overview: Chapter 19 Viruses: A Borrowed Life Overview: Chapter 19 Viruses: A Borrowed Life Viruses called bacteriophages can infect and set in motion a genetic takeover of bacteria, such as Escherichia coli Viruses lead a kind of borrowed life between

More information

Are Immune Modulators Really Needed to Cure HBV infection?

Are Immune Modulators Really Needed to Cure HBV infection? Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,

More information

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...

More information

INFECTIOUS DISEASES. Chapter 13

INFECTIOUS DISEASES. Chapter 13 INFECTIOUS DISEASES Chapter 13 No reproduction or distribution without the prior written consent of McGraw-Hill Education. 1 The Process of Infection Infection: a disease or condition caused by a microorganism

More information

19 Viruses BIOLOGY. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Structural Features and Characteristics

19 Viruses BIOLOGY. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Structural Features and Characteristics 9 Viruses CAMPBELL BIOLOGY TENTH EDITION Reece Urry Cain Wasserman Minorsky Jackson Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV Lecture Presentation

More information

Infection : a disease or condition caused by a microorganism Microorganisms are the tiniest living organisms on earth that

Infection : a disease or condition caused by a microorganism Microorganisms are the tiniest living organisms on earth that Chapter 13: Infectious Diseases The Process of Infection Infection : a disease or condition caused by a microorganism Microorganisms are the tiniest living organisms on earth that eat, reproduce, and die

More information

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( ) Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United

More information

Virus Basics. General Characteristics of Viruses. Chapter 13 & 14. Non-living entities. Can infect organisms of every domain

Virus Basics. General Characteristics of Viruses. Chapter 13 & 14. Non-living entities. Can infect organisms of every domain Virus Basics Chapter 13 & 14 General Characteristics of Viruses Non-living entities Not considered organisms Can infect organisms of every domain All life-forms Commonly referred to by organism they infect

More information

Viruses. Picture from:

Viruses. Picture from: Viruses Understand the structure of bacteriophages & human immunodeficiency virus (HIV) Appreciate that viruses replicate in host cells (thereby destroying them) Picture from: http://eands.caltech.edu/articles/lxvii1/viruses.html

More information

Oncology Market Forecast To 2013

Oncology Market Forecast To 2013 Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

Virus Basics. General Characteristics of Viruses 5/9/2011. General Characteristics of Viruses. Chapter 13 & 14. Non-living entities

Virus Basics. General Characteristics of Viruses 5/9/2011. General Characteristics of Viruses. Chapter 13 & 14. Non-living entities Virus Basics Chapter 13 & 14 General Characteristics of Viruses Non-living entities Not considered organisms Can infect organisms of every domain All life-formsf Commonly referred to by organism they infect

More information

Antiviral Chemotherapy

Antiviral Chemotherapy Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus

More information

Setting The setting was secondary care. The economic study was carried out in the USA.

Setting The setting was secondary care. The economic study was carried out in the USA. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman

More information

Medivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development

Medivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development Medivir at Avanza s Företagsdag 10 december 2008 Lars Adlersson, CEO Börje Darpö, VP Development Medivir contact rein.piir@medivir.se www.medivir.com Medivir Key achievements 2008 Strong phase IIa data

More information

Global Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to 2022

Global Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to 2022 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company

More information

Idenix Pharmaceuticals Building a Leading Antiviral Franchise

Idenix Pharmaceuticals Building a Leading Antiviral Franchise Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen and Company 7 th Annual Global Healthcare Conference November 7, 2006 Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Safe Harbor This

More information